Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 4/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14451165 | 0.86 | FDPS (0.38) | FDPSTSHRARGAAMAPT | |
| SCHEMBL31211936 | 0.82 | FDPS (0.36) | FDPSTSHRARGAAMAPT | |
| SCHEMBL1444746 | 0.82 | FDPS (0.40) | FDPSTSHRARGAAMAPT | |
| SCHEMBL29268091 | 0.82 | AR (0.37) | FDPSTSHRARGAAMAPT | |
| SCHEMBL16861331 | 0.82 | FDPS (0.36) | FDPSTSHRARGAAMAPT | |
| SCHEMBL19222165 | 0.79 | TSHR (0.36) | FDPSTSHRARGAAMAPT | |
| SCHEMBL21996407 | 0.79 | FDPS (0.38) | FDPSTSHRARGAAMAPT | |
| SCHEMBL22210902 | 0.79 | FDPS (0.38) | FDPSTSHRARGAAMAPT | |
| SCHEMBL31678596 | 0.79 | FDPS (0.34) | FDPSTSHRARGAAMAPT | |
| SCHEMBL855608 | 0.77 | DAO (0.38) | FDPSTSHRGAAMAPTNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646410-A1 | TUBULIN POLYMERIZATION INHIBITORS | AB Science (FR) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024146923-A1 | TUBULIN POLYMERIZATION INHIBITORS | AB SCIENCE (FR) | 2024-07-11 | — | — | WO | disclosed |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| CN-101066950-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2007-11-07 | — | — | CN | disclosed |
| CN-101062917-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2007-10-31 | — | — | CN | disclosed |
| CN-101062918-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2007-10-31 | — | — | CN | disclosed |
| CN-1732155-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| EP-1580189-A1 | 4-AMINO-5-METHYLPYRAZOLE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF | Sankyo Agro Company, Limited (JP) | 2005-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | MIF, ASGR1, FCGR2A | FDPS 2297/4885TSHR 943/4885AR 4158/4885 |
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CDC7, BUB1B, CDK7 | FDPS 1764/4885TSHR 4801/4885AR 3485/4885 |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, MAVS | FDPS 1293/4885TSHR 3539/4885AR 3970/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | FDPS 4253/4885TSHR 220/4885AR 335/4885 |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | FDPS 440/4885TSHR 4852/4885AR 4784/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | FDPS 749/4885TSHR 1278/4885AR 2259/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | FDPS 3899/4885TSHR 1182/4885AR 1592/4885 |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | FDPS 3351/4885TSHR 4228/4885AR 3419/4885 |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | EZH2, BMI1, EZH1 | FDPS 2042/4885TSHR 4365/4885AR 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.